Repository logo
 

Physico-chemical requirements and kinetics of membrane fusion of flavivirus-like particles.


Change log

Authors

Espósito, Danillo LA 
Nguyen, Jennifer B 
DeWitt, David C 
Rhoades, Elizabeth 

Abstract

Flaviviruses deliver their RNA genome into the host-cell cytoplasm by fusing their lipid envelope with a cellular membrane. Expression of the flavivirus pre-membrane and envelope glycoprotein genes in the absence of other viral genes results in the spontaneous assembly and secretion of virus-like particles (VLPs) with membrane fusion activity. Here, we examined the physico-chemical requirements for membrane fusion of VLPs from West Nile and Japanese encephalitis viruses. In a bulk fusion assay, optimal hemifusion (or lipid mixing) efficiencies were observed at 37 °C. Fusion efficiency increased with decreasing pH; half-maximal hemifusion was attained at pH 5.6. The anionic lipids bis(monoacylglycero)phosphate and phosphatidylinositol-3-phosphate, when present in the target membrane, significantly enhanced fusion efficiency, consistent with the emerging model that flaviviruses fuse with intermediate-to-late endosomal compartments, where these lipids are most abundant. In a single-particle fusion assay, VLPs catalysed membrane hemifusion, tracked as lipid mixing with the cellular membrane, on a timescale of 7-20 s after acidification. Lipid mixing kinetics suggest that hemifusion is a kinetically complex, multistep process.

Description

Keywords

Animals, Cell Line, Cell Membrane, Chemical Phenomena, Encephalitis Viruses, Japanese, Humans, Hydrogen-Ion Concentration, Kinetics, Lipids, Membrane Fusion, Temperature, Time Factors, Virosomes, West Nile virus

Journal Title

J Gen Virol

Conference Name

Journal ISSN

0022-1317
1465-2099

Volume Title

96

Publisher

Microbiology Society
Sponsorship
National Institute of General Medical Sciences (R01GM102869)
Wellcome Trust (101908/Z/13/Z)
This work was supported by a Senior Research Fellowship from the Wellcome Trust, grant number 101908/Z/13/Z, to Y.M.; grant R01 GM102869 from the National Institutes of Health (NIH) to Y.M.; NIH grant NS079955 to E.R.; NIH grant T32 GM08283 to J.B.N.; and NIH grant T32 GM007223 to D.C.D. We thank Michel Ledizet, Martin Mattessich and Nathalie Bonafé (L2 Diagnostics, LLC) for helpful discussions.